BioCentury | Jan 31, 2020
Product Development

CSL is harnessing its supply chain expertise to expand into cell and gene therapy

CSL aims to leverage the logistics expertise it built through its plasma business to expand into cell and gene therapy. The company has a sickle cell disease program in Phase I and is lining up...
BC Extra | Apr 17, 2019
Clinical News

St. Jude, Mustang gene therapy produces functional immunity in SCID-X1 patients

St. Jude and Mustang reported late Wednesday that their gene therapy led to fully functioning immune systems in newly diagnosed infants with X-linked severe combined immunodeficiency (SCID-X1) who were treated in the Phase I/II LVXSCID-ND...
BC Week In Review | Aug 17, 2018
Company News

Mustang licenses immunodeficiency gene therapy from St. Jude

Mustang Bio Inc. (NASDAQ:MBIO) gained exclusive, worldwide rights to develop and commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital. St. Jude will receive...
BC Extra | Aug 13, 2018
Company News

Mustang licenses immunodeficiency gene therapy from St. Jude

Mustang Bio Inc. (NASDAQ:MBIO) gained exclusive, worldwide rights to develop and commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital. St. Jude will receive...
BC Week In Review | May 19, 2017
Company News

EC opens investigation into Aspen's EU pricing practices

The European Commission began a formal investigation of Aspen Pharmacare Holdings Ltd. (JSE:APN) amid concerns that the company breached EU antitrust rules by excessively raising the prices of five off-patent cancer medicines: chlorambucil, melphalan, mercaptopurine,...
BC Week In Review | Feb 9, 2017
Clinical News

LentiGlobin BB305 gene therapy: Ph I HGB-206 amended

bluebird amended the open-label, U.S. Phase I HGB-206 trial evaluating IV LentiGlobin BB305 to increase production of therapeutic anti-sickling hemoglobin and increase enrollment to up to 29 patients from up to 8. The changes include...
BioCentury | Sep 28, 2015
Emerging Company Profile

Microparticle man

RxMP Therapeutics LLC is developing microparticles harvested from red blood cells to mitigate excessive bleeding during surgery or trauma by promoting clotting at sites of bleeding without instigating unwanted coagulation. Available hemostatics used for acute...
BioCentury | Jun 23, 2014
Product Development

Battling beta T

Data presented at the European Hematology Association meeting this month suggest both bluebird bio Inc. and Acceleron Pharma Inc. could have the first two disease-modifying treatments for beta thalassemia. While bluebird's gene therapy approach could...
BC Week In Review | Nov 4, 2013
Clinical News

Busulipo regulatory update

Pharmalink said FDA granted Orphan Drug designation for Busulipo, a liposome formulation of the generic chemotherapeutic busulfan, as a conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT). The company...
BC Extra | Oct 5, 2013
Financial News

Pharmalink raises $15 million in series C

Pharmalink AB (Stockholm, Sweden) raised SEK96 million ($15 million) in a series C round co-led by new investor Investinor and existing investor Industrifonden. The company's founders, who are existing investors, also participated. Next year, Pharmalink...
Items per page:
1 - 10 of 83